SLC7A11 and neoplasm: Immunohistochemistry analysis revealed that Sorafenib treatment significantly reduced the levels of SLC7A11 and Ki67, a proliferation marker, and increased the level of 4-HNE, a marker of ferroptosis, in tumor tissues (Fig. 7E).